Funding ChallengesThe cash runway is expected to extend to BLA resubmission, depending on FDA requirements, due to additional funds and operation cost cuts.
Regulatory RisksRisks include inability to resubmit the tab-cel BLA in a timely manner, rejection of the tab-cel BLA resubmission by the FDA, and setbacks with other pipeline candidates.
Workforce ReductionAtara announced a reduction in its workforce that will impact approximately 50% of its current employees.